The New York City Department of Health and Mental Hygiene advised health care providers in an alert Thursday of a case of HIV infection in a resident who was reported to have been adherent to HIV pre-exposure prophylaxis (PrEP).
Health officials say the patient has a multidrug resistant strain of the virus, including resistance to the drugs in PrEP.
Evidence of PrEP adherence was demonstrated by sufficient drug levels in hair and blood samples were detected a few weeks after the time of the HIV diagnosis.
NYC health officials note that the medication approved for PrEP, Truvada, is highly effective at preventing HIV infection, but rare episodes of HIV infection are still possible and expected.
The Health Department requests that providers report immediately by phone any HIV diagnosis in a person receiving PrEP or HIV post-exposure prophylaxis (PEP) because of the elevated risk of drug resistant HIV infection.
- Duke researchers findings provide insight for HIV vaccine development
- Forms of HIV can cross from chimps to humans: Nebraska researchers
- HIV therapy for breastfeeding mothers can virtually eliminate transmission to babies